Beranda › Sindrom Mielodisplastik › Oklahoma › Oklahoma City
Uji klinis Sindrom Mielodisplastik di Oklahoma City, OK
3 studi untuk Sindrom Mielodisplastik mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Uji klinis Sindrom Mielodisplastik di kota lain
- Houston, TX43 studi
- Baldwin Park, CA26 studi
- New York City, NY21 studi
- Seattle, WA21 studi
- Washington, DC20 studi
- Tampa, FL19 studi
- Boston, MA19 studi
- Miami, FL17 studi
- Durham, NC14 studi
- Columbus, OH14 studi
- St. Louis, MO13 studi
- Atlanta, GA13 studi
Studi lain di Oklahoma City
- Kanker Paru Non-Sel Kecil28 studi
- Kanker Ovarium28 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal22 studi
- Kanker Prostat21 studi
- Kanker Paru19 studi
- Kanker Payudara17 studi
- Kanker Metastatik16 studi
- Kanker (semua jenis)14 studi
- Leukemia Mieloid Akut14 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Kanker Kandung Kemih11 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.